Skip to main content

Gilead news and events in 2026

Gilead is a biopharmaceutical organization that researches and develops therapeutic treatments. The organization focuses on creating antiviral medications for the treatment of conditions such as HIV, hepatitis B, hepatitis C, influenza, and respiratory viruses.

Public (GILD)Biotechnology Research10,000+ employeesgilead.comLinkedIn

Get Gilead's live signals in Claude or ChatGPT, or by API

AskWhat changed at Gilead this week? Use Autobound signals for gilead.com.
Dated updates
74
Last event
Nov 17, 2026
Open rolesSnapshot Nov 17, 2026
84
Latest SEC filing
Oct 29, 2026

Source: Autobound Signal API · 74 signals tracked for Gilead · updated

Overview

Gilead by topic

Latest events

Latest Gilead events

  1. Revenue
    Generic Lenacapavir Wins FDA Tentative Approval, but U.S. Yeztugo Users Can’t Switch YetGilead Sciences generated $305 million in third-quarter revenue from its HIV prevention drug Yeztugo.
  2. In development
    Gilead reports trial success. Gilead Sciences stock is valued at USD 189.8 billion graduallyGilead reported positive Phase 2 clinical trial results for its investigational oral emvistegrast treatment for ulcerative colitis and plans to launch a Phase 3 study in 2027.
  3. In development
    Gilead Sciences stock reports growth at EUR 133.42, plus 0.02 percentGilead Sciences is developing oral treatments for mosquito-borne flaviviruses, supported by a new federal grant.
  4. New location
  5. Facility expansion
    Gilead opens new building on existing Foster City campusGilead Sciences unveiled a new 182,000 square-foot building on its existing campus in Foster City, which will house oncology and scientific research.
  6. In development
    Gilead Sciences Just Won Its Third FDA Approval in Less Than 4 Months. Is the Stock Still Underrating This Turnaround Play?Gilead Sciences is developing Yeztugo, a once-weekly oral HIV pre-exposure prophylaxis (PrEP) with a PDUFA target date of Feb. 2.
  7. Partnership
  8. Launch
    FDA approves daily HIV pill from Gilead designed to simplify treatment for some patientsGilead Sciences launched its new once-daily HIV pill, Bixlenvo, after receiving approval from the U.S. Food and Drug Administration.
  9. Earnings
    Gilead's Second-Quarter Revenue Rises 8%, Exceeding Wall Street ForecastsGilead Sciences reported an adjusted loss per share of $6.75 for the second quarter, better than the analyst consensus expectation of a $7.24 loss.
  10. Launch
    Will the Label Expansion of Trodelvy Strengthen GILD's Oncology Portfolio?Gilead Sciences received FDA approval for the label expansion of its breast cancer drug Trodelvy for the first-line treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC).

Showing 10 of 20 events. The Signal API returns all of them.

Get them with one API call

Signal API · MCP

Track Gilead with the Signal API

One POST /v1/companies/enrich call with gilead.com returns every signal type for Gilead, each with its source. Or ask Claude through MCP.

2 credits per signal returned; zero-result calls are free. Endpoint reference

curl -X POST https://signals.autobound.ai/v1/companies/enrich \
  -H "X-API-KEY: $AUTOBOUND_API_KEY" \
  -H "Content-Type: application/json" \
  -d '{"domain":"gilead.com","limit":20}'

Bulk data

Need these signals for 10,000+ companies?

Get a free sample file or a bulk feed (API, GCS push, flat file).

Talk to sales

Same industry

Gilead questions

What is the latest news on Gilead?
On Nov 3, 2026, gayety.com reported: Generic Lenacapavir Wins FDA Tentative Approval, but U.S. Yeztugo Users Can’t Switch Yet. This page tracks 20 news events for Gilead since Dec 18, 2025, each with a date and a source link.
What is going on with Gilead?
In the 90 days to Nov 19, 2026, Autobound tracked 8 news events, 1 10-Q filing, 1 8-K filing, 4 hiring snapshots, 25 signals for Gilead. The newest story is from Nov 3, 2026 (Revenue), reported by gayety.com.
Is Gilead laying off employees?
resonategroup.com.ng reported on May 5, 2026: After Arcellx buyout close, Gilead trims 108 jobs at CAR-T biotech's redwood city outpost. Autobound lists 1 reported layoff round for Gilead. Each row states what its source reported, not a confirmed total.
What else does Autobound track for Gilead?
Beyond news and filings, Autobound lists 45+ signals for Gilead from 6 sources: Glassdoor (15+), Website changes (12), Employee growth (7), Patents (6), Reddit (3), Podcasts (2). See the Gilead signals page for the dated list.
Is Gilead hiring right now?
Yes. As of Nov 17, 2026, Gilead had 84 open roles, and Research and development had the most with 10.

Page updated , the date of the newest row on this page.

Source. News, SEC filings (8-K, 10-K, 10-Q, Form D), hiring data and other signals (Reddit, podcasts, Glassdoor, reviews, social posts, patents, web traffic) from the Autobound Signal API.

Method. Stories are grouped when they report the same event within 14 days. Rows that do not name the company are removed. Each row links its source.

Data as of .

How this data is built →Get it from the Signal API →